EUVIMEDEUVIMED entdecken
Netzwerk-MetaanalyseSystematische ÜbersichtOpen Access

Comparative safety of B/F/TAF versus other antiretroviral therapy regimens for treatment-naïve people with HIV-1: a systematic literature review and network meta-analysis

Tristan Curteis, Lucy A Eddowes, Megan Chen, Bhumi Gandhi-Patel, Andrei Karlsson, Hannah Luedke, Manon Rubinstein, Mathias Hempfling, Ernesto G Scerpella, Paresh Chaudhari, James Jarrett

Journal of Comparative Effectiveness Research · 30.05.2025

DOI: 10.57264/cer-2024-0231 ↗

Kurz gefasst

Netzwerk-Metaanalyse in der Zeitschrift Journal of Comparative Effectiveness Research, online erschienen am 30.05.2025. Verfasst von Tristan Curteis und 10 weiteren Autor:innen. Beteiligte Einrichtung: Costello Medical, Manchester, UK. Hauptthemen laut MEDLINE: Adenine, Anti-HIV Agents, Emtricitabine, HIV Infections. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Bictegravir, emtricitabine and tenofovir alafenamide (B/F/TAF) is a single-tablet regimen approved for the treatment of HIV-1 in treatment-naive (TN) and virologically suppressed people with HIV-1 (PWH). While the efficacy of antiretroviral therapy (ART) regimens in TN PWH is well established, regimen selection is often influenced by safety and tolerability concerns. This systematic literature review and network meta-analysis compares the safety outcomes of B/F/TAF with other ART regimens in TN PWH, addressing a key aspect of therapeutic decision-making. Materials & methods: A systematic literature review was performed to identify phase III and IV RCTs assessing B/F/TAF and comparator regimens in TN adults (≥18 years) with HIV-1. MEDLINE, Embase, Cochrane Database of Systematic Reviews and CENTRAL databases were last searched on 14 June 2023. Study design, population and outcome definitions were evaluated to ensure consistency across studies. Bayesian network meta-analyses were conducted where feasible, following key methodological guidelines.

Results

Nineteen studies were included in indirect comparisons following assessments of heterogeneity and network connectivity. B/F/TAF performed better than the majority of interventions in safety and tolerability outcomes, notably discontinuation due to adverse events (AEs), treatment-related AEs and nausea. Additionally, with comparable risk of experiencing grade 3/4 treatment-emergent AEs, diarrhea and all-cause discontinuation rates to other interventions, B/F/TAF was non-inferior to any other regimen for all outcomes. B/F/TAF typically outperformed interventions containing non-nucleoside reverse transcriptase inhibitor third agents in terms of treatment-related AEs, nausea, and discontinuation due to AEs, although treatment class effects were not estimated separately.

Conclusion

This analysis highlights the favorable safety profile of B/F/TAF compared with other ART regimens in TN PWH, demonstrating that B/F/TAF remains a safe and well-tolerated ART option for most TN PWH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdenineAnti-HIV AgentsEmtricitabineHIV InfectionsTenofovirAlanineBayes TheoremHeterocyclic Compounds, 3-RingHeterocyclic Compounds, 4 or More RingsHIV-1PyridonesAmidesPiperazines

Stichwörter der Autor:innen

HIV-1antiretroviral therapynetwork meta-analysissafety and tolerabilitysystematic literature review

Substanzen

AdenineAlanineAnti-HIV AgentsbictegravirEmtricitabineHeterocyclic Compounds, 3-RingHeterocyclic Compounds, 4 or More RingsPyridonesTenofovirtenofovir alafenamide

Autor:innen und Institutionen

  • Costello Medical, Manchester, UK.
  • Costello Medical, Bristol, UK.
  • Gilead Sciences Inc, Foster City, CA, USA.
  • Costello Medical, London, UK.
  • HEOR Consultant, SimulStat Incorporated, Solana Beach, CA, USA.

Zitieren

APA

Curteis, T., Eddowes, L. A., Chen, M., Gandhi-Patel, B., Karlsson, A., Luedke, H., Rubinstein, M., Hempfling, M., Scerpella, E. G., Chaudhari, P., & Jarrett, J. (2025). Comparative safety of B/F/TAF versus other antiretroviral therapy regimens for treatment-naïve people with HIV-1: a systematic literature review and network meta-analysis. Journal of Comparative Effectiveness Research. https://doi.org/10.57264/cer-2024-0231

Vancouver

Curteis T, Eddowes LA, Chen M, Gandhi-Patel B, Karlsson A, Luedke H, et al. Comparative safety of B/F/TAF versus other antiretroviral therapy regimens for treatment-naïve people with HIV-1: a systematic literature review and network meta-analysis. Journal of Comparative Effectiveness Research. 2025. doi:10.57264/cer-2024-0231

BibTeX
@article{Curteis2025,
  author = {Curteis, Tristan and Eddowes, Lucy A and Chen, Megan and Gandhi-Patel, Bhumi and Karlsson, Andrei and Luedke, Hannah and Rubinstein, Manon and Hempfling, Mathias and Scerpella, Ernesto G and Chaudhari, Paresh and Jarrett, James},
  title = {Comparative safety of B/F/TAF versus other antiretroviral therapy regimens for treatment-naïve people with HIV-1: a systematic literature review and network meta-analysis},
  journal = {Journal of Comparative Effectiveness Research},
  year = {2025},
  doi = {10.57264/cer-2024-0231}
}
Kostenlos starten →